Oncology
Sevabertinib Makes HER2 Testing Actionable in NSCLC
The FDA granted accelerated approval to sevabertinib for adults with advanced nonsquamous NSCLC harboring activating HER2 tyrosine kinase domain mutations, making validated genomic identification central to treatment selection.
Rayan Salih · September 10, 2026 · 6 min